DSO acquisition offers are still coming — how to actually evaluate one

Veterinary consolidators — multi-practice groups often backed by private equity, sometimes called DSOs in an analogy to dental service organizations — continue to actively acquire independent practices, and many practice owners are fielding inbound interest whether they’re actively selling or not. Evaluating an offer well requires looking past the headline multiple to terms that matter just as much over the long run.

What’s actually in a typical offer

Most consolidator deals combine an upfront cash payment with some form of continued involvement — an employment agreement keeping the seller on as a working DVM for a defined term, and sometimes an equity rollover into the parent company. The headline multiple usually applies to the cash portion; the rollover and employment terms are where deals actually differentiate from each other.

Questions that matter more than the multiple

What happens to clinical autonomy after close — does the parent company set protocols, vendor relationships, and pricing, or does the practice keep meaningful local control? What’s the actual non-compete and the geographic radius it covers, since that determines your options if the employment term doesn’t work out as expected? And what’s the realistic, not promised, liquidity timeline on any equity rollover — some don’t have a clear exit for years.

Staff retention through a transition

Consolidator acquisitions are a common trigger for staff turnover, particularly among long-tenured techs and associates who built their working relationship around the previous ownership structure. Owners who negotiate retention bonuses or clear communication plans for staff into the deal terms — rather than leaving staff communication to the acquirer’s standard playbook — tend to see less disruption in the months after close.

Walking away is also a valid outcome

Declining an offer, or countering with terms the consolidator won’t meet, is a legitimate result of due diligence — not every offer that looks attractive on the multiple is actually a good fit once autonomy, staff impact, and rollover liquidity are weighed honestly.

Bottom line: evaluate the full deal structure, not the headline multiple — autonomy terms, non-compete scope, and rollover liquidity often matter more to long-run outcome than the upfront number.